^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SynKIR-110

i
Other names: SynKIR-110, autologous T cells transduced with mesothelin KIR-CAR, SynKIR110, SynKIR 110
Company:
University of Pennsylvania, Verismo Therap
Drug class:
Mesothelin-targeted CAR-T immunotherapy
7d
Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies (clinicaltrials.gov)
P=N/A, N=0, Withdrawn, Verismo Therapeutics | N=100 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
SynKIR-110
3ms
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
P1, N=42, Recruiting, Verismo Therapeutics | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Dec 2027
Trial completion date • Trial primary completion date • Metastases
|
MSLN (Mesothelin)
|
SynKIR-110
7ms
New trial
|
SynKIR-110
1year
Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesothelioma (SITC 2023)
These data support further clinical development of SynKIR-110 in patients with advanced solid tumors. SynKIR-110 is currently being investigated in a Phase I clinical trial STAR-101 (NCT05568680).
Preclinical • CAR T-Cell Therapy
|
MSLN (Mesothelin)
|
MSLN positive
|
SynKIR-110
over1year
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
P1, N=42, Recruiting, Verismo Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Mar 2023
Enrollment open • Trial initiation date • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
SynKIR-110
2years
New P1 trial • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
SynKIR-110